Treatment of patients with ER+/FGFR1-amplified breast cancers with letrozole, an aromatase inhibitor, increased the expression of FGFR1 and FGFs, as well as the nuclear localization of FGFR1 and ERα [135]. Here, ESR1 is linked to breast cancer.